• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Ustekinumab Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5759558

MBS5759558 is an inhibitor targeting Ustekinumab. Ustekinumab is an anti-IL-12/IL-23 IgG1kappa human monoclonal antibody. More details

Please Inquire
Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Ustekinumab, Inhibitor
Full Product Name
Ustekinumab
Product Synonym Names
Anti-Human IL-12/IL-23
Form/Format
Solid. Powder
Purity/Purification
99.4%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
148000.00
Solubility
<1mg/ml refers to the product slightly soluble or insoluble
CAS Number
815610-63-0
Target & IC50
IL-12
IL-23
Cell Research
HUVECs are grown on calibrated glass coverslips to a confluency of 80%. Subsequently, cells are incubated with 200ug/mL Ustekinumab AlexaFluor488 and Briakinumab AlexaFluor594 for 20 minutes at 37 degree C, pH 7.3, washed three times, and chased in fresh medium for an additional 20 min before fixation. Antibodies are directly labeled. FcRn binding is quality controlled by SPR analysis. Cells are then counterstained with anti-FcRn monoclonal antibody DVN22, followed by anti-mouse secondary antibodies conjugated to AlexaFluor647. Imaging is performed on a Leica SP8 confocal microscope[2].

Product References and Citations for Ustekinumab, inhibitor

Montepaone M, et al. Profile of ustekinumab and its potential in the treatment,of active psoriatic arthritis. Open Access Rheumatol. 2014 Feb 20;6:7-13.
Montepaone M, et al. Profile of ustekinumab and its potential in the treatment,of active psoriatic arthritis. Open Access Rheumatol. 2014 Feb 20;6:7-13.
Schoch A, et al. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A. 2015 May 12;112(19):5997-6002.
Schoch A, et al. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A. 2015 May 12;112(19):5997-6002.

Other Notes

Small volumes of Ustekinumab, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000